ES2572652T3 - Nuevas formas de un compuesto multicíclico - Google Patents

Nuevas formas de un compuesto multicíclico Download PDF

Info

Publication number
ES2572652T3
ES2572652T3 ES10750210.6T ES10750210T ES2572652T3 ES 2572652 T3 ES2572652 T3 ES 2572652T3 ES 10750210 T ES10750210 T ES 10750210T ES 2572652 T3 ES2572652 T3 ES 2572652T3
Authority
ES
Spain
Prior art keywords
new forms
compound
multicyclic compound
theta
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10750210.6T
Other languages
English (en)
Spanish (es)
Inventor
Stephen Bierlmaier
Michael Christie
Laurent Courvoisier
R. Scott Field
R. Curtis Haltiwanger
Linli He
Martin J. Jacobs
Michael Kress
Robert E. Mckean
Dale R. Mowrey
Joseph Petraitis
Mehran Yazdanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2572652(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Application granted granted Critical
Publication of ES2572652T3 publication Critical patent/ES2572652T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
ES10750210.6T 2009-08-26 2010-08-25 Nuevas formas de un compuesto multicíclico Active ES2572652T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US237180P 2000-10-03
US23718009P 2009-08-26 2009-08-26
PCT/US2010/046671 WO2011028580A1 (en) 2009-08-26 2010-08-25 Novel forms of a multicyclic compound

Publications (1)

Publication Number Publication Date
ES2572652T3 true ES2572652T3 (es) 2016-06-01

Family

ID=43033463

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10750210.6T Active ES2572652T3 (es) 2009-08-26 2010-08-25 Nuevas formas de un compuesto multicíclico

Country Status (19)

Country Link
US (1) US8633314B2 (enExample)
EP (1) EP2470540B1 (enExample)
JP (3) JP2013503173A (enExample)
KR (1) KR20120092100A (enExample)
CN (1) CN102482282A (enExample)
AU (1) AU2010289746B2 (enExample)
BR (1) BR112012004053A2 (enExample)
CA (1) CA2772328C (enExample)
CL (1) CL2012000478A1 (enExample)
DK (1) DK2470540T3 (enExample)
EA (1) EA020756B1 (enExample)
ES (1) ES2572652T3 (enExample)
IL (1) IL218132B (enExample)
MX (1) MX2012002456A (enExample)
MY (1) MY156873A (enExample)
NZ (1) NZ598883A (enExample)
SG (1) SG178852A1 (enExample)
UA (1) UA110604C2 (enExample)
WO (1) WO2011028580A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク. 多環系化合物の新規形態
CA2967828A1 (en) 2014-11-26 2016-06-02 Cephalon, Inc. Crystalline forms of parp inhibitors
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
CN101316592A (zh) * 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク. 多環系化合物の新規形態

Also Published As

Publication number Publication date
CL2012000478A1 (es) 2012-11-05
EP2470540A1 (en) 2012-07-04
JP2018035158A (ja) 2018-03-08
MX2012002456A (es) 2012-05-08
CA2772328A1 (en) 2011-03-10
EA020756B1 (ru) 2015-01-30
EA201270315A1 (ru) 2012-08-30
AU2010289746B2 (en) 2016-07-07
JP2016014029A (ja) 2016-01-28
WO2011028580A1 (en) 2011-03-10
MY156873A (en) 2016-04-15
KR20120092100A (ko) 2012-08-20
NZ598883A (en) 2014-09-26
BR112012004053A2 (pt) 2020-12-08
EP2470540B1 (en) 2016-04-20
AU2010289746A1 (en) 2012-04-12
CA2772328C (en) 2017-06-20
HK1171750A1 (zh) 2013-04-05
CN102482282A (zh) 2012-05-30
US8633314B2 (en) 2014-01-21
UA110604C2 (uk) 2016-01-25
JP2013503173A (ja) 2013-01-31
SG178852A1 (en) 2012-04-27
DK2470540T3 (en) 2016-08-01
US20120214998A1 (en) 2012-08-23
IL218132A0 (en) 2012-06-28
IL218132B (en) 2018-02-28

Similar Documents

Publication Publication Date Title
ES2674174T3 (es) Antagonista de LPA1 policíclico y usos del mismo
CN103387541B (zh) 一种取代吡唑醚类化合物的制备方法
ES2557465T3 (es) Moduladores de la actividad de HEC 1 y procedimientos para ello
ES2587903T3 (es) Compuestos de imidazolidinadiona y sus usos
JP2013523802A5 (enExample)
CN103864670A (zh) 阿普司特的制备方法
JP2009527517A5 (enExample)
HRP20130950T1 (hr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina
JP2015017126A (ja) オロパタジンの製造方法および中間体
US8772327B2 (en) Phenylpropionic acid derivative and use thereof
CN104774195B (zh) 一种光学纯伊曲康唑关键中间体及合成方法以及由该中间体合成光学纯伊曲康唑的方法
US20220372025A1 (en) Method for producing tetracyclic compound
JP2016513060A5 (enExample)
CN101402537B (zh) 2-吡啶-β酮类化合物的应用
ES2665336T3 (es) Compuesto amina y su uso para propósitos médicos
HRP20170023T1 (hr) Kristalni oblik pemirolasta
ES2496465T3 (es) Un procedimiento para la preparación de Etoricoxib
JP2013227563A5 (enExample)
KR102453655B1 (ko) 아코티아미드의 개선된 제조방법
CA2794389A1 (en) Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
HRP20180865T1 (hr) Kristalni oblik abakavira koji uglavnom ne sadrži otapalo
ES2784835T3 (es) Método de preparación de silodosina y sus compuestos intermedios
CN103087039A (zh) 一种多取代苯并[1,3]间二氧杂环戊烷类化合物的合成方法
CN106008372B (zh) 一种达克米替尼的制备方法及其关键中间体
CN104557899A (zh) 一种阿齐沙坦i晶型晶体的制备方法